Literature DB >> 23902702

Association of atrial fibrillation with mortality and disability after ischemic stroke.

Emer R McGrath1, Moira K Kapral, Jiming Fang, John W Eikelboom, Aengus ó Conghaile, Aengus O'Conghaile, Michelle Canavan, Martin J O'Donnell.   

Abstract

OBJECTIVE: We determined whether patient characteristics (age, sex, comorbidities), stroke severity, and quality of care explained a proportion of the association between atrial fibrillation (AF) and increased disability and mortality in patients with acute ischemic stroke.
METHODS: The study included a prospective cohort of consecutive patients admitted with acute ischemic stroke included in the Registry of the Canadian Stroke Network (July 1, 2003 to March 31, 2008). Multivariable logistic regression analyses were used to determine the magnitude of association between AF and modified Rankin score 4-5 at discharge, 30-day mortality, and 1-year mortality.
RESULTS: There were 10,528 patients admitted with acute ischemic stroke. AF was associated with an increased risk of severe disability and mortality, but the magnitude of association was substantially attenuated in the full multivariable models: modified Rankin score 4-5 at discharge (univariate odds ratio [OR] 1.74, 95% confidence interval [CI] 1.57-1.93; multivariable OR 1.19, 95% CI 1.03-1.36), 30-day mortality (univariate OR 2.52, 95% CI 2.25-2.84; multivariable OR 1.36, 95% CI 1.17-1.58), and 1-year mortality (univariate OR 2.41, 95% CI 2.19-2.66; multivariable OR 1.25, 95% CI 1.10-1.42). Older age and increased stroke severity explained most of the association between AF and poor stroke outcomes. We found no association between AF and poor stroke outcomes in patients receiving therapeutic preadmission oral anticoagulant therapy.
CONCLUSIONS: Older age and increased stroke severity explain most of the association between AF and poorer outcomes after acute ischemic stroke. Nonuse of oral anticoagulant therapy represents the most important modifiable care gap to mitigate the association between AF and poor outcomes after ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23902702     DOI: 10.1212/WNL.0b013e3182a2cc15

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  30 in total

Review 1.  Practical issues in the management of novel oral anticoagulants-cardioversion and ablation.

Authors:  Abhishek Maan; E Kevin Heist; Jeremy N Ruskin; Moussa Mansour
Journal:  J Thorac Dis       Date:  2015-02       Impact factor: 2.895

2.  The use of odds ratio in the large population-based studies: Warning to readers.

Authors:  Luigi Di Lorenzo; Valeria Coco; Francesco Forte; Giovanni Felice Trinchese; Alfonso Maria Forte; Marco Pappagallo
Journal:  Muscles Ligaments Tendons J       Date:  2014-05-08

3.  Screening for atrial fibrillation in Canadian pharmacies: an economic evaluation.

Authors:  Jean-Eric Tarride; Lisa Dolovich; Gordon Blackhouse; Jason Robert Guertin; Natasha Burke; Veena Manja; Alex Grinvalds; Ting Lim; Jeff S Healey; Roopinder K Sandhu
Journal:  CMAJ Open       Date:  2017-08-22

Review 4.  Global epidemiology of atrial fibrillation.

Authors:  Faisal Rahman; Gene F Kwan; Emelia J Benjamin
Journal:  Nat Rev Cardiol       Date:  2014-08-12       Impact factor: 32.419

Review 5.  Clinical and Economic Implications of AF Related Stroke.

Authors:  Ali N Ali; Ahmed Abdelhafiz
Journal:  J Atr Fibrillation       Date:  2016-02-29

Review 6.  Developing a Conversation Aid to Support Shared Decision Making: Reflections on Designing Anticoagulation Choice.

Authors:  Claudia L Zeballos-Palacios; Ian G Hargraves; Peter A Noseworthy; Megan E Branda; Marleen Kunneman; Bruce Burnett; Michael R Gionfriddo; Christopher J McLeod; Haeshik Gorr; Juan Pablo Brito; Victor M Montori
Journal:  Mayo Clin Proc       Date:  2019-01-11       Impact factor: 7.616

7.  Adequacy of preadmission oral anticoagulation with vitamin K antagonists and ischemic stroke severity and outcome in patients with atrial fibrillation.

Authors:  Konstantinos Tziomalos; Vasilios Giampatzis; Stella D Bouziana; Marianna Spanou; Stavroula Kostaki; Maria Papadopoulou; Vasiliki Dourliou; Areti Sofogianni; Christos Savopoulos; Apostolos I Hatzitolios
Journal:  J Thromb Thrombolysis       Date:  2016-02       Impact factor: 2.300

8.  Antiplatelet therapy following ischaemic stroke - Continue or change pre-existing therapy?

Authors:  Wardati Mazlan-Kepli; Rachael L MacIsaac; Matthew Walters; Philip Mw Bath; Jesse Dawson
Journal:  Eur Stroke J       Date:  2016-11-04

9.  Mean platelet volume and its genetic variants relate to stroke severity and 1-year mortality.

Authors:  Małgorzata M Miller; Nils Henninger; Agnieszka Słowik
Journal:  Neurology       Date:  2020-06-23       Impact factor: 9.910

10.  Ischemic Stroke Severity and Mortality in Patients With and Without Atrial Fibrillation.

Authors:  Naja E Vinding; Søren L Kristensen; Rasmus Rørth; Jawad H Butt; Lauge Østergaard; Jonas B Olesen; Christian Torp-Pedersen; Gunnar H Gislason; Lars Køber; Christina Kruuse; Søren P Johnsen; Emil L Fosbøl
Journal:  J Am Heart Assoc       Date:  2022-02-12       Impact factor: 6.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.